Guidant CEO Dollens Named To HHS Secretary’s Regulatory Reform Panel
This article was originally published in The Gray Sheet
Executive Summary
Guidant President and CEO Ronald Dollens is part of a 27-member panel appointed by HHS Secretary Tommy Thompson to consider ways to reduce administrative burdens at FDA and the Centers for Medicare & Medicaid Services
You may also be interested in...
Local Review Flaws Signify Opportunity To Improve National Coverage – Wood
A pre-authorization system informing beneficiaries and physicians in advance which procedures are likely to be covered by Medicare is preferable to continued local medical review policies (LMRPs), according to Douglas Wood, MD, Mayo Clinic
Local Review Flaws Signify Opportunity To Improve National Coverage – Wood
A pre-authorization system informing beneficiaries and physicians in advance which procedures are likely to be covered by Medicare is preferable to continued local medical review policies (LMRPs), according to Douglas Wood, MD, Mayo Clinic
Third-Party Reviews Should Be Used Only If Expertise Is Lacking – MDMA
The Medical Device Manufacturers Association is seeking to toughen FDA device reform legislation to prevent outside expert reviews of PMAs from occurring unless the agency lacks resources to conduct the reviews in-house